Evidence map›Paper›PMID 39313837›Full record

ArticleJournal of hepato-biliary-pancreatic sciences2024

Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi-institutional retrospective study.

Yuki Imaoka, Masahiro Ohira, Tsuyoshi Kobayashi, Naruhiko Honmyo, Michinori Hamaoka, Takashi Onoe, Daisuke Takei, Koichi Oishi, Tomoyuki Abe, Toshihiro Nakayama and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepato-biliary-pancreatic sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuki ImaokaDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0003-0882-5341
Masahiro OhiraDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-5433-5303
Tsuyoshi KobayashiDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0001-7364-1798
Naruhiko HonmyoDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Michinori HamaokaDepartment of Gastroenterological, Breast and Transplant Surgery Hiroshima Prefectural Hospital, Hiroshima, Japan.
Takashi OnoeDepartment of Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Daisuke TakeiDepartment of Surgery, Onomichi General Hospital, Onomichi, Japan.ORCID https://orcid.org/0000-0001-7804-8790
Koichi OishiDepartment of Surgery, Chugoku Rosai Hospital, Kure, Japan.
Tomoyuki AbeDepartment of Surgery, National Hospital Organization Higashi Hiroshima Medical Center, Higashihiroshima, Japan.ORCID https://orcid.org/0000-0001-6859-7614
Toshihiro NakayamaDivision of Abdominal Transplant, Stanford University, Stanford, California, USA.
Miho AkabaneDivision of Abdominal Transplant, Stanford University, Stanford, California, USA.
Kazunari SasakiDivision of Abdominal Transplant, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0003-2514-5778
Hideki OhdanDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)

Funding

Japan Agency for Medical Research and Development 24fk0210108Japan Society for the Promotion of Science 22K16535Japan Society for the Promotion of Science 23H02981
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) ranks third in cancer-related deaths globally. Despite treatment advances, high post-hepatectomy recurrence rates (RR), especially with liver fibrosis and hepatitis C virus infection, remain challenging. Key prognostic factors include vascular invasion and perioperative blood loss, impacting extrahepatic recurrence. Natural killer (NK) cells are crucial in countering circulating tumor cells through TRAIL-mediated pathways. The aim of this study was to validate the liver immune status index (LISI) as a predictive tool for liver NK cell antitumor efficiency, particularly in HCC patients with vascular invasion.

methodsA retrospective analysis of 1337 primary HCC hepatectomies was conducted by the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Clinicodemographic data were extracted from electronic medical records. Prognostic indices (FIB-4, ALBI, ALICE, GNRI, APRI, and LISI) were evaluated using area under the receiver operating characteristic curve values. Survival analyses employed Kaplan-Meier estimations and log-rank tests.

resultsLISI significantly correlated with other prognostic markers and stratified patients into risk groups with distinct overall survival (OS) and RR. It showed superior predictive performance for 2-year OS and RR, especially in patients with vascular invasion. Over longer periods, APRI and FIB-4 index reliabilities improved. The HISCO-HCC score, combining LISI, tumor burden score, and alpha-fetoprotein levels, enhanced prognostic accuracy.

conclusionLISI outperformed existing models, particularly in HCC with vascular invasion. The HISCO-HCC score offers improved prognostic precision, guiding immunotherapeutic strategies and individualized patient care in HCC.

Indexed as

Carcinoma, HepatocellularHepatectomyLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPredictive Value of TestsPrognosisRetrospective StudiesRisk Assessmentantitumor activityhepatectomyhepatocellular carcinomanatural killer cells

Identifiers

PMID39313837
PMCPMC11589398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.